Codex DNA, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Todd R. Nelson MBA,
- Full Time Employees
- 212
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 9535 Waples Street San Diego CA United States of America 92121-2993
- IPO Date
- Jun 18, 2021
- CIK
- 0001850079
- Website
- codexdna.com
- Similar Companies
- Business
- Codex DNA, Inc. (NASDAQ: DNAY), now operating as Telesis Bio, develops and commercializes synthetic biology platforms for on-demand DNA and mRNA synthesis, serving biomedical research, therapeutics development, vaccine production, and industrial biotechnology applications worldwide. The company offers the flagship BioXp system, an end-to-end automated benchtop workstation including the BioXp 3250 and BioXp 3200 models for high-throughput gene and mRNA construction; BioXp kits for synthetic DNA, mRNA, variant libraries, and full workflows; benchtop reagents such as Gibson Assembly products and SARS-CoV-2 genomes/RNA controls; and complementary services like custom DNA synthesis, oligo synthesis, and Vmax X2 cells for genetic engineering. Headquartered in San Diego, California, and founded in 2013 as SGI-DNA before rebranding to Codex DNA and subsequently Telesis Bio, the company has deployed approximately 200 BioXp systems globally to academic institutions, biopharmaceutical firms, and research centers. Recent developments include a December 2021 research collaboration and licensing agreement with Pfizer Inc. for enzymatic DNA synthesis in mRNA vaccines and biotherapies, achieving the first technical milestone in December 2022 with additional payments pending; the November 2021 acquisition of EtonBio Inc. to expand DNA sequencing, oligo synthesis, and synthetic biology services; and an ongoing strategic shift under the Telesis Bio name emphasizing antibody discovery, cell/gene therapy, and rapid mRNA workflows via the BioXp platform and Gibson SOLA custom solutions to reduce turnaround times by up to 90%.
Telesis Bio, Inc. (DNAY) Q3 2022 Earnings Call Transcript
Codex DNA (DNAY) Reports Q3 Loss, Tops Revenue Estimates
Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8
Codex DNA (DNAY) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Codex DNA, Inc. (DNAY) CEO Todd Nelson on Q2 2022 Results - Earnings Call Transcript
Codex DNA (DNAY) Reports Q2 Loss, Tops Revenue Estimates
Codex DNA to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
Codex DNA to Present at the 2022 Jefferies Healthcare Conference
Codex DNA, Inc. (DNAY) CEO Todd Nelson on Q1 2022 Results - Earnings Call Transcript
Codex DNA to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
Codex DNA, Inc. (DNAY) CEO Todd Nelson on Q4 2021 Results - Earnings Call Transcript
Codex DNA Announces Registration and Webcast Information for Upcoming R&D Webinar on March 29, 2022
Codex DNA to Report Fourth Quarter 2021 Financial Results on Tuesday, March 22, 2022
Codex DNA to Present at the Cowen 42nd Annual Healthcare Conference
Codex DNA to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space
3 Biotech Stocks To Watch In 2022
Codex DNA Stock (DNAY): Why The Price Surged
Why Codex DNA Trounced the Market Today
Codex DNA, Inc. (DNAY) CEO Todd Nelson on Q3 2021 Results - Earnings Call Transcript